The new facility, which is estimated to cost nearly €40 million, will be used, among other things, to expand production to serve new markets such as China. In the two - story building, which will be constructed on the current Allergopharma premises, products for the diagnosis and treatment of type 1 allergies.
More than two dozen state prosecutors are asking the Food and Drug Administration to reconsider...
Exercise might help women beat breast cancer. A study finds it can ease the achy joints and...
GREER® Labs has announced that the Allergenic Products Advisory Committee (APAC) of the...
Quintiles has announced the appointment of W. Scott Evangelista to serve as president, Integrated Commercial Services and Solutions. In this role, Evangelista is responsible for leading Quintiles’ global Commercial organization and the ongoing development and delivery of its related service offerings.
Global efforts to curb malaria are stalling after a drop in funds to buy bed nets, according to the latest report Wednesday from the World Health Organization. For the second year in a row, WHO noted a dramatic decline in the number of bed nets given out to protect people from the mosquitoes that spread malaria.
Tens of thousands of women each year might be able to skip at least some of the grueling treatments for breast cancer — which can include surgery, heavy chemo and radiation — without greatly harming their odds of survival, new research suggests.
The slow rollout of a new federal health insurance marketplace may be deepening differences in health coverage among Americans, with residents in some states gaining insurance at a far greater rate than others. The demarcation may be as simple as Democrat and Republican.
British Prime Minister David Cameron says he hopes to kick-start an international effort to find a cure or effective treatment for dementia by 2025. At a one-day summit on dementia on Wednesday hosted by the U.K., Cameron declared that discovering a cure or treatment for dementia is "within our grasp."
Emergent BioSolutions has entered into a definitive agreement with Cangene Corporation under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.
AstraZeneca and Bristol-Myers Squibb Company announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommends the investigational medicine metreleptin for the treatment of pediatric and adult patients with generalized lipodystrophy (LD).
ScinoPharm today announced that the company has completed construction of its Changshu plant on a 16-acre site. The facilities, located in Changshu, (Jiangsu province) China, include an R&D process development center and a multipurpose API (active pharmaceutical ingredients) manufacturing plant fully compliant with U.S., EU, and Chinese CGMP standards.
The FDA has approved the first generic versions of Cymbalta (duloxetine delayed-release capsules), a prescription medicine used to treat depression and other conditions.
Roche and Prothena Corporation have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease, which is currently in preclinical development and is expected to enter Phase 1 clinical trials in patients with Parkinson's disease in 2014.
Shares of CytRx Corp. soared Wednesday after the drug developer said its potential cancer treatment fared much better than an established chemotherapy in mid-stage testing on patients with soft-tissue sarcoma.
The U.S. Food and Drug Administration is implementing a plan to help phase out the use of medically important antimicrobials in food animals for food production purposes, such as to enhance growth or improve feed efficiency. The plan would also phase in veterinary oversight of the remaining appropriate therapeutic uses of such drugs.
CVS Caremark and prescription drug distributor Cardinal Health are combining their buying power through a 10-year joint venture to purchase generic medicines. The joint venture will become active in July and will negotiate supply contracts for both Dublin, Ohio-based Cardinal and CVS Caremark, the nation's second largest drugstore chain and one of the largest pharmacy benefits managers.
McKesson Corp.'s $8.3 billion bid to buy rival pharmaceutical drug distributor Celesio AG is facing opposition from a major Celesio shareholder that contends the proposed sales price is too low.
Savient Pharmaceuticals has reached an agreement on the terms of an acquisition with Crealta Pharmaceuticals LLC through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA assets, for gross proceeds of approximately $120.4 million.